ALCESTER, England, September 18, 2017 /PRNewswire/ --
Quanta Dialysis Technologies Ltd ("Quanta" or the "Company"), a medical device company providing innovative haemodialysis solutions for clinic and home settings, today announces that the Company will be exhibiting at the 10th UK Annual Dialysis Conference, taking place from Thursday 28th to Friday 29th September 2017, at the Lowry Hotel in Manchester, UK.
Quanta's Chief Executive Officer, John E. Milad, and Chief Commercial Officer, Peter Hoyer, will be attending the conference. Any parties interested in arranging a meeting are requested to contact enquiries@quantadt.com.
The UK Annual Dialysis Conference theme for 2017 is 'Dialysis fit for the 21st century', which focuses on the challenges, improvements and outcomes faced by dialysis patients and clinicians in the UK. Patients, clinicians and researchers will explore and discuss topics of clinical interest, including effective integrated home dialysis models, clinical challenges in dialysis practice and quality improvement.
About SC+
SC+ is a unique high-performance, easy-to-use, compact haemodialysis system that supports patients across the continuum of care, from the clinic to the home. SC+ provides clinical efficacy and high flow rates comparable to larger, conventional devices and is compatible with traditional treatment regimens used in-centre. The innovative and patented technology behind SC+ is based on a design breakthrough that allows all dialysate fluid management to be conducted on a small, lightweight, disposable cartridge. This cartridge-based design is intended to reduce downtime, simplify treatment complexity and reduce the risk of contamination. SC+ has regulatory approval in Europe (CE mark) and is currently being used to treat patients in the UK.
About Quanta
Quanta aims to improve the lives of dialysis patients by providing advanced haemodialysis solutions for use both in the clinic and the home. Quanta's lead product SC+ is designed to empower dialysis patients by providing them with greater flexibility, convenience and control over the delivery of their life-sustaining renal replacement therapy. Quanta is based in Alcester, UK, and was founded in 2008 as a spin out from IMI plc. The company has attracted funding from a group of leading investors, including: Stage Capital (formerly NBGI Ventures), Wellington Partners, Seroba Life Sciences, b-to-v Partners, ALIAD, Seventure Partners and Kuwait Life Sciences Company, as well as founding partner IMI plc.
For more information, please visit: http://www.quantadt.com.
For more information about Quanta, please contact:
Quanta
John E. Milad
Chief Executive Officer
T: +44(0)1789-400043
E: enquiries@quantadt.com
Consilium Strategic Communications
Amber Fennell / Matthew Neal / Lindsey Neville
T: +44(0)203-709-5708
E: quanta@consilium-comms.com
